Last reviewed 2026-05-20 · How we verify

Serum containing Avonex

Biogen · Phase 1 active Small molecule ✓ Verified May 2026

Serum containing Avonex is a Small molecule drug developed by Biogen. It is currently in Phase 1 development. Also known as: Avonex.

Avonex is a protein-based medication used to treat Multiple Sclerosis, as indicated by ClinicalTrials.gov. It is administered in serum, which is a protein-containing liquid, according to its modality as a protein as listed on ChEMBL.

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Biogen is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Serum containing Avonex
Also known as	Avonex
Sponsor	Biogen
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Serum containing Avonex CI brief — competitive landscape report
Serum containing Avonex updates RSS · CI watch RSS
Biogen portfolio CI

Frequently asked questions about Serum containing Avonex

What is Serum containing Avonex?

Serum containing Avonex is a Small molecule drug developed by Biogen.

Who makes Serum containing Avonex?

Serum containing Avonex is developed by Biogen (see full Biogen pipeline at /company/biogen).

Is Serum containing Avonex also known as anything else?

Serum containing Avonex is also known as Avonex.

What development phase is Serum containing Avonex in?

Serum containing Avonex is in Phase 1.

Manufacturer: Biogen — full pipeline
Also known as: Avonex

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing